Kazia Therapeutics Limited (KZIA)

Market Cap	5.06M
Revenue (ttm)	15,650
Net Income (ttm)	-10.68M
Shares Out	23.63M
EPS (ttm)	-0.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	139,312
Open	0.217
Previous Close	0.217
Day's Range	0.210 - 0.229
52-Week Range	0.190 - 1.280
Beta	2.05
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 9, 2024

About KZIA

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 6, 1999
• Employees: 9
• Stock Exchange: NASDAQ
• Ticker Symbol: KZIA

Financial Performance

In 2023, KZIA's revenue was 23,000, a decrease of -14.81% compared to the previous year's 27,000. Losses were -20.47 million, -18.19% less than in 2022.

Financial numbers in AUD